Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib.

@article{Falchook2013MerkelCP,
  title={Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib.},
  author={Gerald Steven Falchook and Peter Rady and Sharon R Hymes and Harrison Phu Nguyen and Stephen K Tyring and Victor G Prieto and David S. Hong and Razelle Kurzrock},
  journal={JAMA dermatology},
  year={2013},
  volume={149 3},
  pages={322-6}
}
IMPORTANCE Approximately 10% to 25% of patients treated with BRAF inhibitors develop cutaneous squamous cell carcinoma (SCC), but the mechanism responsible has not yet been determined. We report what we believe to be the first case in which Merkel cell polyomavirus (MCPyV) and human papillomavirus subtype 17 (HPV-17) were associated with cutaneous SCC that developed during treatment with the BRAF inhibitor dabrafenib. OBSERVATIONS A 62-year-old woman with V600E BRAF -mutant metastatic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Improved survival with vemurafenib in melanoma with BRAF V 600 E mutation

  • F Su, A Viros, C Milagre
  • N Engl J Med
  • 2011

Similar Papers

Loading similar papers…